HGH Fragment 176-191
Also known as: Frag 176-191, AOD-9401, GH Fragment
The fat-burning fragment of human growth hormone without anabolic effects.
Overview
HGH Fragment 176-191 represents the tail portion of the HGH molecule responsible for its lipolytic effects. Unlike full HGH, this fragment does not compete for GH receptors or affect IGF-1 levels, providing targeted fat loss benefits.
Mechanism of Action
Mimics the lipolytic region of growth hormone, directly stimulating fat cell breakdown through beta-adrenergic mechanisms. Does not affect glucose metabolism or cellular proliferation.
Pharmacokinetics
Very short half-life (15-30 minutes) requiring multiple daily doses for optimal effect.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Standard
250-500 mcg
Twice daily
8-12 weeks
Morning and pre-exercise, fasted
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Demonstrated lipolytic activity without hyperglycemia
- 2No effect on longitudinal growth or IGF-1
- 3Preferential reduction in abdominal fat in animal studies
Side Effects & Contraindications
Reported Side Effects
- Injection site reactions
- Hypoglycemia (rare)
Contraindications
- Pregnancy
- Active malignancy
Safety Considerations
Limited human data. Theoretically safer than full HGH due to lack of growth-promoting effects.
Storage Requirements
Store lyophilized at -20C. Reconstituted stable at 2-8C for 14 days.
Scientific References
- 1